BloombergSarepta Surges After U.S. Regulators Delay Ruling on DMD DrugBloombergSarepta Therapeutics Inc. surged in early trading after the biotechnology company said U.S. regulators had delayed ruling on its drug for a deadly muscle disease, raising hopes that the therapy could be approved. The Food and Drug Administration ...Sarepta Saga Drags On as FDA Delays Decision on Duchenne DrugXconomyFDA Is Said to Delay Decision on Duchenne Muscular Dystrophy DrugNew York TimesFDA delays decision on Sarepta's muscle-wasting disorder drugReutersFierceBiotech -CNBC -Bidness ETC -StreetInsider.comall 50 news articles »

BING NEWS:
  • An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting
    The FDA advisory panel review of Sarepta's DMD drug eteplirsen will be surprising ... and I've covered U.S. Food and Drug Administration advisory committee meetings for just as long.
    04/24/2016 - 5:45 am | View Link
  • Sarepta Bolstered by Doctor Letter Urging FDA Approval of DMD Drug
    36 doctors, all experts in Duchenne muscular dystrophy, have written a letter to the U.S. Food and Drug Administration ... to accelerate the approval of a DMD drug, without mentioning eteplirsen ...
    03/21/2016 - 6:07 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News